Cerulean Pharma Inc. Fund Company Profile

Description

Cerulean Pharma Inc., a clinical-stage company, develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the United States. The company’s lead product candidate is CRLX101, a tumor targeted nanoparticle-drug conjugate (NDC), which is in Phase 2 clinical development in patients with renal cell carcinoma; and in Phase 2 and Phase 1b clinical development in patients with ovarian cancer. It is also developing CRLX301, a platform-generated NDC clinical candidate, which is in Phase 1/2a clinical trials. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Waltham, Massachusetts.